Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The iron-responsive element (IRE) in the 5'-untranslated region (5'-UTR) of alpha-synuclein (SNCA) mRNA is a conserved RNA stem-loop structure that regulates the translation of alpha-synuclein in response to cellular iron levels (Rogers et al., 2011, J. Neurochem.). Under low-iron conditions, iron-regulatory proteins (IRPs) bind to this IRE, physically blocking the recruitment of the 43S pre-initiation complex and inhibiting translation (Moussaud et al., 2014, Exp. Neurol.). Conversely, high iron levels cause IRPs to dissociate, leading to increased alpha-synuclein synthesis, which can contribute to protein aggregation in neurodegenerative diseases (Favetta et al., 2019, Front. Neurosci.). This target is of significant interest in the treatment of synucleinopathies, such as Parkinson's disease and Lewy body dementia, where alpha-synuclein accumulation is a hallmark pathology (Chen et al., 2021, J. Biol. Chem.). Small molecule drugs like Posiphen (Buntanetap) are designed to bind to or stabilize the IRE-IRP complex, thereby reducing the translation of SNCA mRNA and lowering total alpha-synuclein protein levels (Annovis Bio, 2023). By decreasing the concentration of alpha-synuclein, these therapies aim to prevent the formation of toxic oligomers and insoluble fibrils that lead to neuronal death (Moussaud et al., 2014, Exp. Neurol.). This approach represents a disease-modifying strategy that targets the root cause of protein misfolding by controlling protein production at the translational level (Rogers et al., 2011, J. Neurochem.).
Translational inhibition via stabilization of the iron-responsive element (IRE) stem-loop structure or enhancement of iron-regulatory protein (IRP) binding to the 5'-UTR of SNCA mRNA.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-synuclein mRNA 5'-untranslated region iron-responsive element (SNCA IRE).